Compare SCVL & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCVL | AUTL |
|---|---|---|
| Founded | 1978 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 491.1M | 407.2M |
| IPO Year | 1994 | 2025 |
| Metric | SCVL | AUTL |
|---|---|---|
| Price | $17.20 | $1.56 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 418.7K | ★ 1.2M |
| Earning Date | 05-29-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.90 | N/A |
| Revenue | ★ $1,135,324,000.00 | $10,120,000.00 |
| Revenue This Year | $1.64 | $80.32 |
| Revenue Next Year | $2.51 | $53.96 |
| P/E Ratio | $9.68 | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $15.04 | $1.15 |
| 52 Week High | $26.54 | $2.70 |
| Indicator | SCVL | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 41.99 | 56.28 |
| Support Level | $16.80 | $1.22 |
| Resistance Level | $18.37 | $1.69 |
| Average True Range (ATR) | 0.72 | 0.08 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 12.14 | 57.63 |
Shoe Carnival Inc is a family footwear retailer that offers a broad assortment of dress, casual, and athletic footwear for men, women, and children with an emphasis on national name brands such as Nike, Skechers, Adidas, Puma, HEYDUDE, Converse, Vans, and Crocs. The company operates its business as one reportable segment based on the similar nature of products sold; merchandising, distribution, and marketing processes involved; target customers; and economic characteristics of stores and e-commerce platforms. Its bricks-first, omnichannel approach provides customers easy access to a wide assortment of branded footwear for work, athletics, daily activities, and special events via a choice of delivery channels.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.